Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

ProPhase Labs, Inc. PRPH

Healthcare — Diagnostics & Research

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
60.12%

Capital & Financial Ratios

Market Cap
1.17
Revenue
3.16
Net Income
(22.46)
Free Cash Flow
(5.53)
Net Debt
5.65
Current Ratio
0.05
Debt/Equity
(1.82)
P/E ratio
0.00
P/S ratio
0.04
P/B ratio
0.00
Past 5Y EPS Growth
(57.56%)
This Y EPS Growth
78.54%
Next Y EPS Growth
55.91%
Next 5Y EPS Growth
—
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2022 0.00
—
—
2021 0.00
—
2020 ‡‡‡
2019 0.00
—
—
2018 0.00
—
—
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 4.74 0.68 0.09 0.02
Receivables 35.81 20.06 1.54 1.54
Inventory 2.29 1.14 0.07 0.07
Other 2.79 6.14 — —
47.59 30.64 3.15 2.80
2023 2024 2025 Q'26
Payables 8.64 13.72 40.56 43.37
ST’ Debt — 3.21 5.16 5.59
Other 3.42 2.12 2.71 3.40
20.86 32.13 53.08 58.09
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 0.48 1.01 — —
—
’25 1.43 1.25 0.88 0.78
4.35
’24 2.36 1.50 1.42 1.49
6.77
’23 19.30 13.22 8.37 (5.90)
34.98
’22 47.53 29.09 24.20 21.82
122.65
’21 15.27 9.14 9.47 45.16
79.04
’20 1.89 3.62 3.84 5.16
14.51
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (0.75) (0.08) — —
—
’25 (3.38) (0.25) (3.49) (1.23)
(8.34)
’24 (5.14) (4.84) (4.04) (3.52)
(17.54)
’23 0.48 (6.96) (4.65) (0.75)
(11.89)
’22 20.29 4.82 2.63 0.81
28.55
’21 (7.89) 4.44 (5.52) (4.65)
(13.62)
’20 0.29 4.37 (0.48) (6.77)
(2.59)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (0.74) (0.08) — —
—
’25 (3.33) (0.18) (3.49) (1.23)
(8.22)
’24 (6.01) (4.69) (3.96) (3.56)
(18.21)
’23 (2.94) (7.62) (5.32) 1.96
(13.93)
’22 19.28 4.43 2.16 (0.78)
25.08
’21 (11.82) 4.13 (14.61) (4.62)
(26.92)
’20 0.17 4.34 (0.56) (8.65)
(4.70)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.43) (0.22) — —
—
’25 1.10 (1.10) (1.60) —
(1.74)
’24 (0.70) (3.30) (3.50) —
(26.10)
’23 0.30 (2.00) (3.00) (5.10)
(9.80)
’22 6.80 4.00 0.60 (0.80)
10.20
’21 0.60 (0.90) (2.60) 6.80
4.00
’20 (0.70) 0.10 (0.40) (0.08)
(1.80)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 62.00 40.50 6.10 0.41 — — —
Low Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 152.50 99.40 74.80 9.30 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 129 113 96 19 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.95 0.31 0.07 0.23 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 122.65 34.98 6.77 4.35 ‡‡‡‡‡ — —
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 57.61% 44.47% (2.22%) 31.85% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 22.91 (22.40) (42.33) (23.39) ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 18.68% (64.02%) (625.26%) (538.25%) ‡‡‡ — —
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 18.46 (16.78) (53.36) (14.74) ‡‡‡‡‡ — —
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.07 6.60 8.13 10.30 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 77.40 20.33 3.39 0.51 ‡‡‡‡‡ — —
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡ 11.70 (9.80) (26.10) (1.74) ‡‡‡‡‡ — —
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 18.02 (6.91) (8.77) (0.98) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.19) (1.18) (0.34) 0.01 ‡‡‡ — —
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 15.83 (8.09) (9.11) (0.97) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 40.16 28.70 3.68 0.41 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.58 1.72 2.00 8.49 ‡‡‡‡‡ — —
Shares
‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ 7.98 0.00 0.00 0.00 ‡‡‡‡‡ — —
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.24 2.28 2.25 0.88 ‡‡‡ — —
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.38 1.62 2.07 1.09 ‡‡‡ — —
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.12 2.55 4.72 2.19 ‡‡‡‡ — —
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.46 (6.41) (1.76) (1.16) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 28.55 (11.89) (17.54) (8.34) ‡‡‡ — —
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.47) (2.04) (0.68) 0.12 — — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 25.08 (13.93) (18.21) (8.22) — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 44.76 26.73 (1.50) (49.93) — — —
Working Cap'
‡‡‡‡‡ — — — ‡‡‡‡‡ ‡‡‡‡‡ 2.70 11.43 17.45 5.79 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (14.74) 6.69 16.77 5.70 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 63.63 49.38 7.35 3.51 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 20.87% (18.69%) (68.80%) (23.96%) ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 30.16% (23.65%) (100.08%) (122.44%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 30.20% (29.70%) (188.11%) (271.49%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

ProPhase Labs (PRPH), a diagnostics and biopharma player that pivoted from OTC products to COVID-19 testing, embodies biotech’s event-driven volatility: revenues exploded from $14.5 million in 2020 to a $122.6 million peak in 2022 (+745% cumulative), fueled by high-margin test kits and gross margins hitting 57.6%, before collapsing 72% to $34.9 million in 2023 and 81% to $6.8 million in 2024 amid demand evaporation and negative margins. The stock mirrored this, surging to near-record highs (up ~100,000% from current levels) before a >90% drawdown, with revenue-gross margin correlation at r≈0.85 and revenue-stock linkage at r≈0.92 underscoring stark cyclicality far beyond biotech norms.

Profitability swung wildly—EBT margins from +19% in 2022 to -625% in 2024, ROE from 30% to -188%, and free cash flow flipping from +$15.83/share to burns—exacerbated by 29x share dilution to 20.5 million (projected 41.5 million in 2025) and rising debt, eroding book value per share 91%. Valuations now appear depressed at 2.3x PS, 2.1x PB, and 0.1x forward sales, contrasting sector medians.

Analyst forecasts offer rebound hope: revenues tripling to $21.4 million in 2025 (+215% YoY) and $41.7 million in 2026, with EBT turning positive at $11.8 million, though EPS remains negative at -$0.56 due to dilution. Price targets imply massive upside (~100,000%), but Monte Carlo models flag 40% rebound odds amid regulatory risks and no insider buys—positioning PRPH as a high-asymmetry mean-reversion play for tactical longs.

Read full commentary →

ProPhase Labs, Inc. (PRPH) Latest News

News by impact score

Fine-tune

15 Apr

4 , 9:05 AM
ProPhase Labs, Inc. (PRPH) reported year-end 2025 results, highlighting accelerating settlement activity and an investment-ready Crown Medical Collections Platform. Year-end results with accelerating settlements and investment-ready platform indicate major strategic advancements boosting future growth and investor interest.

17 Mar

3 GlobeNewswire, 8:00 AM
ProPhase Labs issued a business update highlighting advancing collections activity at Crown Medical. Advancing collections activity signals improved cash flow and operational efficiency with moderate potential to boost financial performance.

3 Feb

4 GlobeNewswire, 7:00 AM
ProPhase Labs, Inc. is exploring a potential sale or strategic partnership for its BE-Smart™ product while also advancing its Crown Medical Collections initiative. These moves are part of the company's broader strategy to enhance its market position and operational efficiency. The potential sale or partnership of BE-Smart™ and the advancement of the Crown Medical Collections initiative could significantly impact ProPhase Labs' strategic direction and financial performance.

2 Feb

3 GlobeNewswire, 8:00 AM
ProPhase Labs, Inc. (PRPH) is hosting an exclusive live investor webinar and Q&A session on February 3rd. The event aims to provide insights into the company's operations and future plans, allowing investors to engage directly with management. The webinar may influence investor sentiment and provide insights into the company's future, but its overall impact is expected to be limited.

26 Jan

4 GlobeNewswire, 7:00 AM
ProPhase Labs, Inc. has provided an update on its Crown Medical collections, revealing that over 250 insurance payors are now engaged. The company is currently in advanced settlement discussions for approximately 50 matters, indicating progress in its collection efforts and potential for improved financial outcomes. Engagement with over 250 insurance payors and advanced settlements could significantly enhance ProPhase Labs' financial performance and market position.

22 Jan

4 GlobeNewswireSimply Wall St.Insider MonkeyBarchartMT NewswiresSimply Wall St.Simply Wall St.Simply Wall St., 7:00 AM
ProPhase Labs, Inc. has successfully uplisted from the Pink Sheets to the OTC Market, enhancing its visibility and accessibility to investors. This transition is expected to improve trading liquidity and attract a broader investor base, potentially leading to increased market interest and investment in the company. Uplisting to the OTC Market is a significant strategic move that can enhance investor confidence and market presence.

5 Jan

3 GlobeNewswireMT NewswiresMT NewswiresSimply Wall St.Simply Wall St., 5:00 AM
ProPhase Labs, Inc. provided an update on its convertible debt conversions, capital structure, and the underlying asset value. The company highlighted recent conversions of debt into equity, which have positively impacted its capital structure. Additionally, ProPhase emphasized the value of its assets, suggesting a strong foundation for future growth and stability. The updates on debt conversions and capital structure may moderately influence financial performance and investor sentiment.

19 Dec

4 , 8:51 AM
ProPhase Labs, Inc. (PRPH) has signed a letter of intent with Advanced Biological Laboratories for a reverse merger. This strategic move aims to enhance ProPhase's capabilities and market presence in the biotechnology sector. The merger is expected to provide ProPhase with additional resources and expertise, potentially accelerating its growth and innovation in the industry. The reverse merger is a significant strategic move that could enhance ProPhase's market position and growth potential.

4 GlobeNewswireGuruFocus.comMT NewswiresMT NewswiresMedical Device NetworkInsider MonkeyInsider MonkeyMT Newswires, 7:00 AM
ProPhase Labs, Inc. has signed a non-binding Letter of Intent (LOI) for a proposed reverse merger with Advanced Biological Laboratories. This strategic move aims to enhance ProPhase's capabilities and market position in the biotechnology sector. The merger is expected to facilitate growth and expand the company's portfolio, although it remains subject to due diligence and definitive agreements. The proposed reverse merger could significantly alter ProPhase Labs' strategic direction and market positioning.

4 Business WireGuruFocus.comMT NewswiresMT NewswiresMedical Device NetworkMT NewswiresInsider MonkeyMT Newswires, 2:00 AM
ABL Diagnostics announced a non-binding letter of intent for a proposed reverse merger between ABL S.A. and ProPhase Labs, Inc. (Nasdaq: PRPH). This potential merger aims to enhance ProPhase's market position and operational capabilities. Further details regarding the merger's structure and implications for both companies are yet to be disclosed. A proposed reverse merger could significantly alter ProPhase Labs' strategic direction and market presence.

3 , 10:30 AM
ProPhase Labs, Inc. (PRPH) has been identified as one of the most active stocks in the market, reflecting heightened trading activity and investor interest. The company's recent developments and market positioning have contributed to its visibility among investors, indicating potential shifts in market dynamics. Increased trading activity suggests a moderate influence on market sentiment and potential financial performance.

26 Nov

4 transcript GuruFocus.comGuruFocus.comGuruFocus.com, 8:01 PM
ProPhase Labs, Inc. reported its Q3 2025 earnings, highlighting strategic initiatives aimed at enhancing growth and financial performance. The company outlined key developments in its product lines and market positioning, emphasizing efforts to innovate and expand its reach. Financial results showed a positive trajectory, reflecting the impact of these initiatives on overall performance. Management expressed confidence in future prospects, citing ongoing investments and strategic partnerships as critical to sustaining momentum. Significant strategic initiatives and positive financial results are likely to influence the company's future performance and investor sentiment.

3 GlobeNewswire, 8:00 AM
ProPhase Labs, Inc. (PRPH) is hosting an exclusive live investor webinar and Q&A session on December 1. The event aims to provide insights into the company's operations and future plans, allowing investors to engage directly with management. Participants will have the opportunity to ask questions and gain a deeper understanding of ProPhase Labs' strategic direction. The webinar may influence investor sentiment and provide insights into the company's future plans, but its overall impact is expected to be limited.

20 Nov

4 app.moby.co, 8:30 AM
ProPhase Labs, Inc. (PRPH) Q3 2025 earnings call summary details quarterly financial results, operational updates, strategic initiatives, and forward guidance. Q3 earnings call summary highlights financial performance and strategic moves with potential to significantly alter PRPH's trajectory and investor sentiment.

29 Oct

4 GlobeNewswire, 8:30 AM
ProPhase Labs, Inc. announced the publication of its BE-Smart study on esophageal cancer in the Official Journal of the American College of Gastroenterology. The study focuses on the effectiveness of a new diagnostic approach for esophageal cancer, aiming to improve early detection and treatment outcomes. This publication is expected to enhance the company's reputation in the oncology field and may lead to further research and development opportunities. The publication of the study could significantly enhance ProPhase Labs' credibility and market position in oncology diagnostics.

28 Oct

3 GlobeNewswire, 8:00 AM
ProPhase Labs, Inc. has engaged RedChip Companies to lead its investor relations efforts. This partnership aims to enhance the company's visibility and communication with investors, potentially improving market engagement and shareholder relations. Engaging a dedicated investor relations firm can moderately influence market sentiment and investor engagement.

24 Oct

3 GlobeNewswire, 8:00 AM
ProPhase Labs, Inc. (PRPH) is set to present at the 2025 ThinkEquity Conference, highlighting its ongoing commitment to innovation and growth in the health and wellness sector. The conference will provide an opportunity for the company to showcase its latest developments and engage with investors and industry leaders. Participation in the conference may enhance visibility and investor interest, but it is not expected to lead to immediate significant changes in the company's trajectory.

22 Oct

4 GlobeNewswire, 7:30 AM
ProPhase Labs, Inc. announced that a study validating its BE-Smart Esophageal Cancer Test has been accepted for publication in the Journal of Clinical Gastroenterology and Hepatology. This test aims to improve early detection of esophageal cancer, potentially enhancing patient outcomes and positioning ProPhase Labs favorably in the oncology diagnostics market. The acceptance of the study in a reputable journal indicates significant validation of the BE-Smart test, which could enhance market positioning and investor sentiment.

23 Sep

4 www.thestreet.com, 1:41 PM
ProPhase Labs, Inc. has filed for Chapter 11 bankruptcy for three of its laboratories while simultaneously exploring a potential cryptocurrency initiative. The company aims to restructure its operations and address financial challenges through this legal process, which may involve selling assets or seeking new investment opportunities. Filing for Chapter 11 bankruptcy and exploring a new business model in cryptocurrency are significant strategic moves that could alter the company's trajectory and investor sentiment.

4 GlobeNewswire, 8:00 AM
ProPhase Labs, Inc. has completed a significant step in its $50 million accounts receivable initiative for Crown Medical Collections. This initiative aims to enhance the company's financial position and operational efficiency by improving cash flow and collection processes. The completion of this step is expected to positively impact ProPhase Labs' overall business strategy and market performance. The completion of the $50 million A/R initiative is a major strategic move that could significantly enhance ProPhase Labs' financial performance and operational efficiency.

12 Sep

3 Associated Press Finance, 10:30 AM
ProPhase Labs, Inc. (PRPH) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. The company's recent developments and market performance have attracted attention, suggesting potential shifts in investor sentiment and market dynamics. Increased trading activity may moderately influence investor sentiment and market positioning.

15 Aug

4 transcript GuruFocus.com, 1:00 PM
ProPhase Labs, Inc. (PRPH) reported its Q2 2025 earnings, highlighting strategic initiatives aimed at enhancing growth and market presence. The company emphasized its focus on product innovation and expansion into new markets, which are expected to drive future revenue. Management provided insights into operational efficiencies and upcoming product launches that could positively impact financial performance. The call also addressed challenges faced in the current market landscape and outlined plans to navigate these effectively. Significant strategic moves and product innovations are expected to alter the company's trajectory and investor sentiment.

12 Aug

4 , 8:00 AM
ProPhase Labs, Inc. has received full approval from the U.S. Patent and Trademark Office (USPTO) for a patent that protects its risk assessment technology for esophageal adenocarcinoma. This patent is expected to enhance the company's position in the market by providing a competitive edge in cancer risk assessment and potentially expanding its product offerings in the healthcare sector. The patent approval is likely to significantly enhance ProPhase Labs' competitive positioning and market opportunities in the healthcare sector.

3 , 10:30 AM
ProPhase Labs, Inc. (PRPH) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. The company is involved in the health and wellness sector, focusing on innovative products and solutions. Recent developments may suggest potential growth opportunities or shifts in market dynamics that could influence its performance. Increased trading activity may lead to moderate influence on market sentiment and financial performance.

29 Jul

3 GlobeNewswire, 8:00 AM
ProPhase Labs, Inc. has announced a special meeting of shareholders and filed a preliminary proxy statement. The meeting will address important corporate matters, and the proxy statement outlines the proposals to be voted on by shareholders. Details regarding the date and agenda of the meeting are included, emphasizing the company's commitment to shareholder engagement and transparency. The shareholder meeting and proxy statement may influence investor sentiment and corporate governance but are not expected to fundamentally alter the company's trajectory.

26 Jun

3 , 7:30 AM
ProPhase Labs, Inc. has received an additional 180-day extension from Nasdaq to regain compliance with the minimum bid price rule. This extension allows the company more time to meet the required bid price of $1 per share, which is necessary to maintain its listing on the exchange. The company is actively working to improve its stock price and ensure compliance with Nasdaq regulations. The extension provides ProPhase Labs with crucial time to stabilize its stock price, potentially affecting its market performance.

17 Jun

4 GlobeNewswire, 7:30 AM
ProPhase Labs, Inc. announced the successful completion of a validation study for its BE-Smart™ molecular diagnostic test, achieving over 95% success in detecting biomarkers related to esophageal cancer. This test can be used with both brush and forceps biopsies, enhancing its clinical applicability. The company plans to accelerate commercialization, targeting a market worth approximately $10 billion. The BE-Smart test addresses critical needs in early detection and monitoring of esophageal diseases, including Barrett’s esophagus and esophageal adenocarcinoma, which has seen a significant increase in incidence and mortality rates. The successful validation and upcoming commercialization of the BE-Smart test represent a significant strategic move that could enhance ProPhase's market position and financial performance.

6 Jun

4 , 7:00 AM
ProPhase Labs, Inc. has established a Clinical Science Advisory Board aimed at expediting the commercialization of its BE-SmartTM diagnostic platform for esophageal diseases. This initiative is expected to enhance the company's capabilities in developing and marketing innovative diagnostic solutions. The formation of a Clinical Science Advisory Board is a significant strategic move that could enhance product development and market positioning.

21 May

3 GuruFocus.com, 5:00 PM
ProPhase Labs Inc (NASDAQ:PRPH) reported significant cost reductions, including a headcount cut from 96 to 25 employees, and sold its manufacturing facility, boosting shareholders' equity from $7 million to $15 million. The company is optimistic about collecting over $20 million in uncollected accounts receivable and is exploring strategic alternatives for Nebula Genomics. However, it faces challenges with COVID testing reimbursements, is under NASDAQ's $1 minimum stock price requirement, and has experienced dilution from financial restructuring. CEO Ted Carcass indicated that commercialization of the BSmart test will take several years, with initial patient testing expected later this year, and confirmed that Nebula Genomics is generating about $5 million annually. Payments from Crown Medical for COVID testing are anticipated in June. ProPhase has accessed some debt financing to bridge liquidity gaps. The company's strategic moves and potential revenue from new products may moderately influence its financial performance.

20 May

4 GlobeNewswire, 8:00 AM
ProPhase Labs, Inc. reported Q1 2025 financial results, highlighting a net revenue decrease to $1.4 million and a net loss of $4.7 million. The company has implemented significant cost reductions, including divesting its Pharmaloz operations and shutting down its genomics lab, saving over $8 million annually. ProPhase anticipates multiple liquidity events, including a potential sale of its subsidiary Nebula Genomics and recovery of $50 million in insurance payments through Crown Medical Collections. The BE-Smart Esophageal Cancer Test study has been submitted for peer review, aiming for commercialization later this year. A virtual conference call is scheduled for May 20, 2025, to discuss these developments. Significant strategic moves and potential liquidity events could alter the company's trajectory and investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us